Anti-TNFRSF8/CD30 Reference Antibody (brentuximab vedotin)
产品介绍
Brentuximab 是一种抗 CD30 单克隆抗体。Brentuximab 与单甲基 auristatin E (MMAE) 偶联生成的抗体-偶联药物 Brentuximab vedotin 可以诱导原发性积液淋巴瘤细胞凋亡 (apoptosis)。Brentuximab vedotin 具有抗肿瘤活性，对人类 CD30+ 癌细胞的 IC50 为 10 nM。
产品性质
产品特色
For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
应用案例
本产品仅用作科学研究！
Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) is 98.99%, determined by SEC-HPLC.
Immobilized human CD30 His at 2 ug/mL can bind Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin), EC50=0.006007 ug/mL.
MMAE is conjugated by sulfhydryl coupling,the DAR value of Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) antibody is 4.0.
存储条件
-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.
COA
已发表文献
相关产品
联系我们
